Kevetrin hydrochloride


Catalog No. Size PriceQuantity
M12806-2 2mg solid $90
M12806-10 10mg solid $270

Description

Kevetrin hydrochloride is a small molecule and activator of the tumor suppressor protein p53, with potential antineoplastic activity. Target:p53 in vitro: Kevetrin activates p53 which in turn induces the expressions of p21 and PUMA (p53 up-regulated modulator of apoptosis), thereby inhibiting cancer cell growth and causing tumor cell apoptosis. Kevetrin may be effective in drug-resistant cancers with mutated p53. p53 tumor suppressor, a transcription factor regulating the expression of many stress response genes and mediating various anti-proliferative processes, is often mutated in cancer cells. in vivo: Kevetrin has demonstrated potent anti-tumor efficacy against various carcinoma xenograft models: lung, breast, colon, prostate and squamous cell carcinoma, and in a leukemia tumor model. In drug-resistant cell lines, Kevetrin has shown excellent activity, galvanizing the Company to focus on Kevetrin's development potential in this area.

Product information

CAS Number: 66592-89-0

Molecular Weight: 179.67

Formula: C5H10ClN3S

Synonym:

4-Isothioureidobutyronitrile hydrochloride

thioureidobutyronitrile hydrochloride

thioureido butyronitrile hydrochloride

Chemical Name: 4-(carbamimidoylsulfanyl)butanenitrile hydrochloride

Smiles: Cl.NC(=N)SCCCC#N

InChiKey: NCXJZJFDQMKRKM-UHFFFAOYSA-N

InChi: InChI=1S/C5H9N3S.ClH/c6-3-1-2-4-9-5(7)8;/h1-2,4H2,(H3,7,8);1H

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO : ≥ 40 mg/mL (222.63 mM)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥360 days if stored properly.

Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

References:

  1. Han D., Smalley K. (2015) Targeting the Cell Cycle and p53 in Combination with?BRAF-Directed Therapy. In: Sullivan R. (eds) BRAF Targets in Melanoma. Cancer Drug Discovery and Development, vol 82. Springer, New York, NY

Products are for research use only. Not for human use.

Payment & Security

American Express Diners Club Discover JCB Mastercard PayPal Venmo Visa

Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.

Estimate shipping

You may also like

Recently viewed